Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: Preparation, characterization, pharmacokinetics and biodistribution studies

Journal of Microencapsulation

Volumn 28, Issue 6, 2011, Pages 515-527

  Dodiya, Shamsunder S ^a   Chavhan, Sandip S ^a   Sawant, Krutika K ^a   Korde, Aruna G ^b  

^a M S UNIVERSITY OF BARODA   (India)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Bioavailability; Particle size; Saturation solubility; Solid state studies

Indexed keywords

SAQUINAVIR; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; SOLID STATE; SUSPENSION; X RAY DIFFRACTION;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; LIPIDS; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; SAQUINAVIR; SOLUBILITY; X-RAY DIFFRACTION;

EID: 80051752420     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.590612     Document Type: Article

References (39)

1. Agueros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Controlled Rel, 2010;145 (1):2-8.
2. Arulsudar N, Subramanian N, Mishra P, Sharma RK, Murthy RSR. Preparation characterization and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine. J Drug Target, 2003;11:187-96. (Pubitemid 37236332)
3. Briesen HV, Ramge P, Kruter J. Controlled release of antiretroviral drugs. AIDS Rev, 2000;2:31-8. (Pubitemid 30479319)
4. Cavalli R. The effect of components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie, 1998;53:392-6. (Pubitemid 28293594)
5. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 2001;13:123-33. (Pubitemid 32288781)
6. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) protease. Antiviral Res, 1991;16:295-305.
7. Dupre J, Behme MT, Hramiak IM, Macfarlane P, Williamson MP, Zabel P, Mcdonoland TT. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes, 1995;44:626-30.
8. Freitas C, Muller RH. Co-relation between long-term stability of solid lipid nanoparticles (SLNs) and crystallinity of the lipid phase. Eur J Pharm Biopharm, 1999;47:125-32. (Pubitemid 29185115)
9. Grant DJW, Brittian HG, 1995. Solubility of pharmaceutical solids. In: Brittian HG, editor. Physical Characterization of Pharmaceutical Solids. New York: Marcel Dekker. pp. 322-80.
10. Hu LD, Tang X, Cue FD. Solid lipid nanoparticles to improve oral bioavail-ability of poorly soluble drugs. J Pharm Pharmacol, 2004;56:1527-35. (Pubitemid 39601993)
11. Irache G, Poncela J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev, 1998;34:191-219.
12. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol, 1989;41:809-12. (Pubitemid 20112141)
13. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J. Safety and activity of saquinavir in HIV infection. Lancet, 1995;345:952-5.
14. Kuo Y, Su F. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm, 2007;340 (1-2):143-52. (Pubitemid 47043350)
15. Lai F, Wissing SA, Muller RH, Fadda AM. Artemisia arborescens L essential oil-loaded solid lipid nanoparticles for potential agricultural application: Preparation and characterization. AAPS PharmSciTech, 2006;7:E1-9.
16. Li Y, Taulier N, Rauth AM, Wu X. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharm Res, 2006; 23 (8):1877-87. (Pubitemid 44200552)
17. Maincent P, Thouvenot P. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res, 1992;9:1534-39.
18. Manjunath K, Venkateswarlu V. Pharmacokinetics tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Controlled Rel, 2005;107:215-28. (Pubitemid 41319672)
19. Mathot F, Beijsterveldt L, Preat V, Brewster M, Arien A. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Controlled Rel, 2006;111:47-55. (Pubitemid 43289994)
20. Muller RH, Mader KS, Gohla A. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 2000;50:161-77. (Pubitemid 30326695)
21. Noble S, Faulds D. Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection. Drugs, 1996;52:93-112.
22. Otsuka M, Kaneniwa N. Effect of seed crystals on solid state transformation of polymorphs of chloramphenicol palmitate during grinding. J Pharm Sci, 1986;75:506-11. (Pubitemid 16083650)
23. Palla BJ, Shah DO. Stabilization of high ionic strength slurries using surfactant mixtures: Molecular factors that determine optimal stability. J Colloid Interface Sci, 2002;256:143-52. (Pubitemid 36164586)
24. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmcol, 2004;56:827-40. (Pubitemid 38885975)
25. Reddy LH, Murthy R. Etoposide-loaded nanoparticles made from glyceride lipids: Formulation characterization in vitro drug release and stability evaluation. AAPS PharmSciTech, 2005;6:158-66.
26. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IV. Rational design of peptide based HIV protease inhibitors. Science, 1993;248:358-61.
27. Robins T, Plattner J. HIV protease inhibitors: Their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr, 1993;6:162-70. (Pubitemid 23082870)
28. Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul, 2008;2:120-35.
29. Shin S, Bum J, Choi J. Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gel in rabbits. Int J Pharm, 2000;209:37-43.
30. Sigfridsson K, Forresen S, Hollander P, Skantze U, Verdier J. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm, 2007;67:540-7. (Pubitemid 47225040)
31. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and a-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm, 2010;389 (1-2):207-12.
32. Su Y, Lee SH, Sinko PJ. Practical aspects of transporter model systems: A case study involving SQV. Drug Metab Rev, 2004;36 (2):377-89. (Pubitemid 38802493)
33. Taburet AM, Sabine PB, Gilles P, Molina JM. Once daily administration of antiretroviral. Clin Pharmacokinet, 2003;42:1179-91.
34. Tsai Y, Jan W, Chien C, Lee W, Lin L, Tsai T. Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. Food Chem, 2011;127 (3):918-25.
35. Venkataraju MP, Gowda DV, Rajesh KS, Shivakumar HG. Xanthum and locust bean gum (from certonia siliqua) matrix tablets for oral controlled delivery of metoprolol tartarate. Curr Drug Ther, 2008;3:70-7.
36. Vivek K, Reddy H, Murthy RS. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech, 2007;8 (4):E1-7.
37. Vyas T, Sahiwala A, Amili M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm, 2008;347:93-101. (Pubitemid 350180312)
38. Wu MS, Robbins JC, Ponpinom MM, Shen TV. Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim Biophys Acta, 1981;674:19-29. (Pubitemid 12243509)
39. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res, 1999;16:751-7. (Pubitemid 29227107)